Payment overview · 2025
General Payments
$257.00
17 reported records · 10 companies
Healthcare provider profile · identity verified
Derek M Brickner, MD
Allopathic & Osteopathic Physicians|Family Medicine · JAMESTOWN, ND · NPI 1346405602
Verified facts
What the public records show
CMS Open Payments records show Derek M Brickner, MD received $257.00 in general payments during 2025 across 17 reported records.
Novartis Pharmaceuticals Corporation accounted for 19.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $50.94 | 19.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $43.83 | 17.1% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.73 | 15.1% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.41 | 12.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.17 | 6.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.01 | 6.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.87 | 6.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.31 | 6.0% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $15.04 | 5.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.69 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $257.00 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $50.94 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $43.83 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $43.83 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $38.73 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.41 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $15.31 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
142 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 509 | 115 |
| Lisinopril | Lisinopril | 444 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 400 | 73 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 390 | 101 |
| Furosemide | Furosemide | 382 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 364 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 354 | 89 |
| Losartan Potassium | Losartan Potassium | 344 | 76 |
| Omeprazole | Omeprazole | 335 | 84 |
| Gabapentin | Gabapentin | 314 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 300 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 299 | 60 |
| Allopurinol | Allopurinol | 270 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 207 | 50 |
| Simvastatin | Simvastatin | 198 | 38 |
| Metformin Hcl Er | Metformin Hcl | 196 | 47 |
| Eliquis | Apixaban | 142 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 140 | 17 |
| Sertraline Hcl | Sertraline Hcl | 127 | 24 |
| Metformin Hcl | Metformin Hcl | 117 | 33 |
| Carvedilol | Carvedilol | 115 | 26 |
| Donepezil Hcl | Donepezil Hcl | 110 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 108 | 46 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 107 | 23 |
| Lorazepam | Lorazepam | 98 | 20 |
| Tramadol Hcl | Tramadol Hcl | 98 | 26 |
| Trazodone Hcl | Trazodone Hcl | 98 | 20 |
| Finasteride | Finasteride | 94 | 17 |
| Potassium Chloride | Potassium Chloride | 93 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | suppressed |
| Bupropion Xl | Bupropion Hcl | 85 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 16 |
| Jantoven | Warfarin Sodium | 81 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 17 |
| Famotidine | Famotidine | 79 | 28 |
| Pregabalin | Pregabalin | 78 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 31 |
| Warfarin Sodium | Warfarin Sodium | 72 | 15 |
| Ozempic | Semaglutide | 69 | 13 |
| Montelukast Sodium | Montelukast Sodium | 66 | 18 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | 14 |
| Atenolol | Atenolol | 61 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 13 |
| Alendronate Sodium | Alendronate Sodium | 59 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 59 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 15 |
| Jardiance | Empagliflozin | 57 | 14 |
| Ezetimibe | Ezetimibe | 56 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 56 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | suppressed |
| Prednisone | Prednisone | 53 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 13 |
| Humalog Kwikpen U-100 | Insulin Lispro | 51 | suppressed |
| Mounjaro | Tirzepatide | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 11 |
| Spironolactone | Spironolactone | 48 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | 11 |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 45 | 45 |
| Celecoxib | Celecoxib | 44 | 17 |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 41 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Klor-Con M20 | Potassium Chloride | 39 | suppressed |
| Trulicity | Dulaglutide | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Alprazolam | Alprazolam | 35 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 35 | suppressed |
| Glimepiride | Glimepiride | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | suppressed |
| Cephalexin | Cephalexin | 31 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 31 | 13 |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Carbamazepine Er | Carbamazepine | 24 | suppressed |
| Gavilyte-C | Peg3350/Sod Sulf,bicarb,cl/Kcl | 24 | 23 |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Diazepam | Diazepam | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Nystatin | Nystatin | 20 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Klor-Con M10 | Potassium Chloride | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 13 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Prevalite | Cholestyramine | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $257.00 · 17 records | Novartis Pharmaceuticals Corporation | Auvelity, Dexcom G6 Transmitter, EVENITY, Jornay PM, LEQVIO, MOUNJARO, NURTEC ODT, PROLIA, QULIPTA, REXULTI, UBRELVY, VOQUEZNA, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error